Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
4 clinical trials · 4 recruiting · INDUSTRY
Trials by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
RECRUITINGPhase 2NCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed...
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 23020 locations
Multiple Myeloma
RECRUITINGPhase 1NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel...
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and...
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 14719 locations
Multiple Myeloma
RECRUITINGPhase 1NCT05869955
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases...
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases...
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 27020 locations
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathySystemic Sclerosis+1
RECRUITINGPhase 1NCT06220201
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing...
The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS),...
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyEnrolling: 12020 locations
Multiple SclerosisMyasthenia Gravis